Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of DYX116 for overweight or obesity in non-diabetic Chinese adults
CTR20261894Phase 2Active
- Sponsor
- Jiangsu Deyuan Pharmaceutical
- Start
- May 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of DYX116 in obesity, Overweight, sponsored by Jiangsu Deyuan Pharmaceutical. Started May 2026; status: active.
02
Drugs
DYX116
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20261894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261894.